Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104225 | 0.88 | — | — | |
| SCHEMBL17369631 | 0.88 | SIGMAR1 (0.45) | SIGMAR1JAK2JAK1TYK2HTR2C | |
| SCHEMBL13884246 | 0.88 | SIGMAR1 (0.45) | SIGMAR1JAK2JAK1TYK2HTR2C | |
| Hydrochloric Acid SCHEMBL21879609 | 0.85 | — | — | |
| SCHEMBL9911345 | 0.84 | SIGMAR1 (0.40) | SIGMAR1JAK2JAK1TYK2HTR2C | |
| SCHEMBL13638689 | 0.84 | SIGMAR1 (0.40) | SIGMAR1JAK2JAK1TYK2HTR2C | |
| SCHEMBL15200275 | 0.84 | SIGMAR1 (0.40) | SIGMAR1JAK2JAK1TYK2HTR2C | |
| SCHEMBL104968 | 0.80 | — | — | |
| SCHEMBL105260 | 0.80 | HTT (0.41) | SIGMAR1HTR2CHTT | |
| SCHEMBL21775731 | 0.80 | OPRK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | SIGMAR1 4583/4885JAK2 1041/4885JAK1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.